A Phase II/III Randomized Double-blind Placebo-Controlled Multi-Center Study of 2 Potential Disease Modifying Therapies in Individuals at Risk for and with Dominantly Inherited Alzheimer?s Disease

J
Jared Brosch, MD

Primary Investigator

Overview

The purpose of this research study is to test two potential disease modifying therapies versus placebo for the treatment of Alzheimer?s disease to determine if one or both prevent, delay, or reverse the changes in the brain that are associated with the development of disease symptoms.

Description

The purpose of this research study is to test two potential disease modifying therapies versus placebo for the treatment of Alzheimer?s disease to determine if one or both prevent, delay, or reverse the changes in the brain that are associated with the development of disease symptoms.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Alzheimer's Disease
  • Age: Between 18 Years - 80 Years
  • Gender: All

Inclusion Criteria
Diagnosed with one of the Alzheimer gene mutations
Exclusion Criteria
Diagnosed with another disorder of the central nervous system
Diagnosed with HIV or hepatitis B or C
History of cancer
Currently pregnant

Updated on 20 Nov 2022. Study ID: 1307011925

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center